- Home
- ENTA
as 11-21-2024 4:00pm EST
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Upcoming Earnings Alert:
Get ready for potential market movements as Enanta Pharmaceuticals Inc. ENTA prepares to release earnings report on 25 Nov 2024.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 245.4M | IPO Year: | 2013 |
| Target Price: | $19.67 | AVG Volume (30 days): | 114.1K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.51 - $17.80 | Next Earning Date: | 11-25-2024 |
| Revenue: | $71,960,000 | Revenue Growth: | -10.71% |
| Revenue Growth (this year): | -8.29% | Revenue Growth (next year): | 5.14% |
Latest Enanta Pharmaceuticals Inc. News
ENTA Breaking Stock News: Dive into ENTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable
Insider Monkey
a month ago
Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline
GuruFocus.com
a month ago
Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares
Zacks
2 months ago
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
BioPharma Dive
2 months ago
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
MT Newswires
2 months ago
Enanta Pharmaceuticals Says Phase 2a Trial of Potential RSV Treatment Meets Endpoints
Business Wire
2 months ago
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
Business Wire
3 months ago
Enanta Pharmaceuticals to Participate in Investor Conferences in September
Compare ENTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENTA Enanta Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.